结直肠癌奥沙利铂、5-Fu耐药的临床相关性研究

Study on the multidrug resistance of colorectal cancer between oxaliplatin and 5-Fu

目的对结直肠癌根治术后接受奥沙利铂(LOHP)、5-Fu辅助化疗患者的耐药性进行评价。方法对在我院接受LOHP方案辅助化疗的150例患者的临床资料进行回顾性分析。包括两种化疗方案:LOHP联合持续灌注5氟尿嘧啶(5-Fu)和亚叶酸钙(CF)的两周方案(A组)、LOHP联合快速输注5-Fu和CF的3周方案。结果 A组治疗总有效率为43.9%,B组治疗总有效率为35.29%,两组比较有差异;两组均有一定的毒副反应,两组比较无差异。结论科学合理配伍使用奥沙利铂和5-Fu能有效拮抗辅助化疗的耐药性,延长结直肠癌患者寿命。

Objective To analyze the drug resistance of colorectal patients which received adjuvant chemotherapy based on oxaliplatin and 5-Fu after operation.Methods Clinical data of 150 patients who had received adjuvant chemotherapy based on oxaliplatin and 5-Fu in our hospital were analyzed retrospect tively.There were two different chemotherapy regimens： Biwee-ekly oxaliplatin combined with continuous intravenous infused 5-Fu and leucovorin（LV）（FOLFOX4）,triweekly oxaliplatin combined with bolus 5-Fu and LV（LOHP/Fu/LV）.Results FOLFOX4 treatment group total effective rate was 43.9%,LOHP/Fu/LV group treatment efficiency was 35.29%,there were significant difference;the two group had a certain toxicity,no significant difference.Conclusion Scientific and reasonable use of compatibility of oxaliplatin and 5-Fu can effectively antagonize adjuvant chemotherapy drug resistance,prolong the life of patients with colorectal cancer.